Gain Therapeutics, Inc. Common Stock
$1.72
$0.01 (+0.58%)
$1.70Day Range$1.79
Key Statistics
Market Cap
$75.07M
Shares Outstanding
43.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 18, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.73
Day High
$1.79
Day Low
$1.70
Volume
265.9K
VWAP
$1.72
Prev Close
$1.71
Transactions
--
Acc. Volume
--
About Gain Therapeutics, Inc. Common Stock
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
PHARMACEUTICAL PREPARATIONSSIC 283421 employees4800 HAMPDEN LANE, BETHESDA, MD, 20814(301) 500-1556IPO Mar 18, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001819411
- Composite FIGI
- BBG00W7D7CJ9
- Share Class FIGI
- BBG00W7D7CK7
- Ticker Root
- GANX
- SIC Code
- 2834
About Gain Therapeutics, Inc. Common Stock (GANX) Stock
Gain Therapeutics, Inc. Common Stock (GANX) closed the 2026-09-16 session at $1.72, up 0.58% versus the previous close (+0.01). The stock opened at $1.73 and traded between $1.70 and $1.79 during that session. Session trading volume was 266K shares. The volume-weighted average price (VWAP) is $1.72.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Gain Therapeutics, Inc. Common Stock has a market capitalization of $75.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. GANX is listed on the XNAS exchange. The company employs approximately 21 people. Gain Therapeutics, Inc. Common Stock is headquartered in BETHESDA, MD. The recorded listing date is 2021-03-18.
On this page you can find market GANX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.